Project Grant R36DA062213

Award Date 2/1/25
Completion Date 1/31/27
Dollars Obligated $54K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Virginia, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $390,635 to the University of Pittsburgh to develop a novel intervention targeting prenatal depressive symptoms to encourage tobacco and cannabis cessation among pregnant and postpartum individuals from marginalized communities. The key objectives are to: 1) conduct formative research with a community collaborative to contextualize the role of...
This $4.68 million project grant from the National Institute on Drug Abuse, part of the Department of Health and Human Services, will fund research under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The University of Michigan will conduct a prospective cohort study of 400 adults with opioid-involved polysubstance use in Michigan. Researchers will collect detailed weekly data on participants' substance use patterns and motivations over four weeks to understand nuanced profiles...
This Project Grant award, valued at $398,972 and beginning on September 1, 2024, is funded by the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality (AHRQ) under the Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) program. The award will support a comprehensive mixed-methods study to examine hospital care practices and outcomes for newborns with prenatal substance exposure. The key objectives are to: 1) survey hospitals in the Better...
This $356,829 Project Grant award, provided by the Maternal and Child Health Bureau under the Maternal and Child Health Federal Consolidated Programs (CFDA 93.110), aims to reduce health disparities in maternal and child health (MCH) outcomes. The key objectives are to: Examine cannabis communication received during prenatal care visits across states and over time, including variations in communication received across maternal sociodemographic characteristics, social determinants of health,...
This $2,112,744 project grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to generate evidence about the incidence of drug-related morbidities and maternal mortality among people who use drugs during pregnancy and the postpartum period. The study will analyze data from a longitudinal hospital database spanning 17 states from 2017-2022 and a CDC maternal mortality database from 2018-2022 to determine spatiotemporal...
This federal Project Grant award, valued at $187,143.00 and provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), funds a pilot study on maternal and paternal alcohol and cannabis use before, during, and after pregnancy. The University of California, San Diego (UCSD) will recruit 100 pregnant individuals who used cannabis and alcohol in the three months prior to pregnancy, along with their male partners, to characterize...
This $1,871,814 project grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will establish a Patient Engagement Resource Center (PERC) to address disparities in substance use disorder (SUD) treatment engagement for parents. The key products and services to be delivered through this 5-year award include: Forming a Lived Expertise Advisory Panel (LEAP) of 18 parents with SUD to support capacity building and...
This $6,439,263 federal Project Grant awarded by the National Institute on Drug Abuse (CFDA 93.279 Drug Abuse and Addiction Research Programs) aims to determine the impact of maternal substance use on maternal immune activation, placental function, and offspring neurobehavioral development. The project will leverage the Healthy Brain and Child Development (HBCD) study to perform maternal immune profiling, placental and cord blood analysis, and novel neuroinflammation imaging on 400 pregnancies...
This $385,000 federal Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support a comprehensive analysis of treatment patterns, outcomes, and predictive factors for patients with co-occurring opioid use disorder (OUD) and alcohol use disorder (AUD). The research aims to assess the effectiveness of integrated treatment approaches, including first-line OUD and AUD medications as well as glucagon-like peptide-1...
This Project Grant award is provided by the National Institutes of Health under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Washington University in St. Louis. The $1,873,868 grant will fund a study titled "Substance Use in Pregnant People - Optimizing Retention in Treatment by Maximizing Opportunities for Management (SUPPORT-MOM)". The study aims to develop and pilot a standardized approach to addressing social determinants of health and implementing a...

A MIXED METHODS EXPLORATION OF PRENATAL POLYSUBSTANCE USE - PROJECT SUMMARY/ABSTRACT SUBSTANCE USE DURING PREGNANCY CAN LEAD TO NEGATIVE MATERNAL AND INFANT OUTCOMES. POLYSUBSTANCE USE IN PREGNANCY IS PARTICULARLY SALIENT CONSIDERING THAT THE INCREASE IN NUMBER OF SUBSTANCES USED CARRIES THE COMPOUNDED RISK FOR BOTH THE MOTHER AND FETUS OF EACH INDIVIDUAL SUBSTANCE, AS WELL AS POTENTIAL NEGATIVE INTERACTIONS BETWEEN SUBSTANCES. PRENATAL POLYSUBSTANCE USE IN THE U.S. IS INCREASING, AND UNDERSTANDING OF THE BEHAVIORAL PATTERNS OF SUCH USE IS CRITICAL. CURRENT RESEARCH SUPPORTS THE RELATIONSHIP BETWEEN PRENATAL INDIVIDUAL SUBSTANCE USE AND BIOPSYCHOSOCIAL FACTORS. HOWEVER, THERE IS LIMITED RESEARCH EXAMINING RELATIONSHIPS BETWEEN SOCIAL DETERMINANTS OF HEALTH (SDOH) AND PRENATAL POLYSUBSTANCE USE. THIS INFORMATION IS IMPORTANT GIVEN THAT EXPOSURE TO ADVERSE SDOH FACTORS CAN INCREASE THE LEVEL OF STRESS EXPERIENCED BY INDIVIDUALS, WHICH SUBSEQUENTLY INCREASES RISK FOR EXPERIENCING SUBSTANCE USE ISSUES, POSING AN EQUITY ISSUE FOR SUCH VULNERABLE POPULATIONS. THE OVERALL OBJECTIVE OF THIS RESEARCH WILL BE TO BETTER UNDERSTAND PRENATAL POLYSUBSTANCE USE IN THE U.S. BY APPROACHING THE CHARACTERIZATION IN TWO WAYS (QUALITATIVE AND QUANTITATIVE) THROUGH A SOCIOECOLOGICAL LENS, AND TRIANGULATING FINDINGS. SPECIFICALLY, THIS PROJECT WILL: 1) CONDUCT QUALITATIVE INTERVIEWS AMONG PREGNANT OR POSTPARTUM PEOPLE ENGAGING IN PRENATAL POLYSUBSTANCE USE TO UNDERSTAND THE BIOPSYCHOSOCIAL CONTEXT OF SUCH BEHAVIORS, AND 2) UTILIZE AN EXISTING NATIONAL PREGNANCY SURVEY (CDC PRAMS) TO QUANTITATIVELY ESTABLISH PSYCHOSOCIAL OUTCOMES OF POLYSUBSTANCE USE BEHAVIORS AMONG PREGNANT PEOPLE, WHICH WILL BE THE FIRST TO INCORPORATE SDOH INTO SUCH A MODEL. FIRST, 20 QUALITATIVE INTERVIEWS WILL BE CONDUCTED WITH PREGNANT OR POSTPARTUM PEOPLE ENGAGING IN POLYSUBSTANCE USE TO UNDERSTAND THE EXPERIENCES AND ENVIRONMENT THAT SURROUNDS SUCH USE. SECOND, THE FINDINGS OF THESE INTERVIEWS WILL INFORM AN EXPLORATION OF PRESENT-DAY PATTERNS OF PREGNANT POLYSUBSTANCE USE USING CDC PRAMS DATA. THESE PATTERNS WILL BE CHARACTERIZED USING LATENT CLASS ANALYSIS (LCA) TO DEFINE UNIQUE GROUPS OF POLYSUBSTANCE USE, WITH THE FIVE SDOH HEALTH DOMAINS AS EXTERNAL VALIDATORS: ECONOMIC STABILITY, EDUCATION ACCESS AND QUALITY, HEALTHCARE ACCESS AND QUALITY, NEIGHBORHOOD AND BUILT ENVIRONMENT, AND SOCIAL AND COMMUNITY CONTEXT. THE STRENGTH OF THIS APPROACH LIES IN THE SPECIFICITY OF QUANTITATIVE ANALYSES, WHILE BEING COMPLEMENTED BY THE DEPTH OF LIVED EXPERIENCES. THIS RESEARCH WILL BE THE FIRST TO OUR KNOWLEDGE TO DETERMINE THE RELATIONSHIP QUANTITATIVELY AND QUALITATIVELY BETWEEN SDOH AND PRENATAL POLYSUBSTANCE USE IN THE U.S. THIS DISSERTATION PROJECT WILL LAY THE FOUNDATION FOR FUTURE WORK TO DETERMINE FACTORS WE MAY BE ABLE TO TARGET FOR PREVENTION, TREATMENT, AND INITIATIVES TO DECREASE THE BURDEN OF PRENATAL POLYSUBSTANCE USE.

Posted 1/16/25, 12:00 AM